D46.1 Refractory anemia with ring sideroblasts

Name of the Condition

• Refractory anemia with ring sideroblasts

Summary

Refractory anemia with ring sideroblasts is a type of myelodysplastic syndrome (MDS) characterized by low red blood cell counts (anemia) and abnormal red blood cell precursors called ring sideroblasts in the bone marrow. The condition is termed "refractory" because it does not respond to standard treatments for anemia. It may progress to acute myeloid leukemia (AML) in some cases.

Causes

The exact cause of refractory anemia with ring sideroblasts is often unknown. It may involve genetic mutations that disrupt normal blood cell production. Other factors can include previous chemotherapy or radiation therapy, exposure to certain chemicals (e.g., benzene), and rarely, inherited bone marrow failure syndromes.

Risk Factors

• Age (most common in individuals over 60)
• Previous cancer treatment with chemotherapy or radiation
• Exposure to industrial chemicals like benzene
• Family history of MDS or other blood disorders
• Certain genetic conditions (e.g., Fanconi anemia)

Symptoms

• Fatigue or weakness
• Frequent infections
• Easy or unexplained bruising or bleeding
• Shortness of breath
• Pale skin
• Unexplained weight loss

Diagnosis

Diagnosis involves a complete blood count (CBC) to identify anemia and other cytopenias, followed by a bone marrow biopsy to assess cell dysplasia and confirm the presence of ring sideroblasts. Cytogenetic analysis may be performed to detect chromosomal abnormalities, and additional tests may evaluate iron metabolism or rule out other conditions.

Treatment Options

• Supportive care, including blood transfusions and antibiotics
• Growth factors (e.g., erythropoiesis-stimulating agents) to improve red blood cell production
• Iron chelation therapy if iron overload occurs from transfusions
• Clinical trials for investigational therapies
• In some cases, stem cell transplantation may be considered

Prognosis and Follow-Up

Prognosis varies depending on factors like age, cytogenetic findings, and response to treatment. Regular follow-up with blood counts and bone marrow evaluations is typically recommended to monitor disease progression. Some patients may remain stable for years, while others may experience worsening cytopenias or progression to AML.

Complications

• Increased risk of infections due to low white blood cell counts
• Bleeding or bruising from low platelet counts
• Iron overload from repeated blood transfusions
• Progression to acute myeloid leukemia (AML)
• Fatigue and reduced quality of life from chronic anemia

Lifestyle & Prevention

• Avoid exposure to known toxins like benzene or certain chemotherapy agents
• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Follow up regularly with healthcare providers for monitoring
• Discuss any new symptoms or concerns promptly

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained bruising or bleeding, frequent infections, or shortness of breath. These symptoms may indicate worsening cytopenias or disease progression and require prompt evaluation.

Tips for Medical Coders

When coding for refractory anemia with ring sideroblasts (ICD10CM code D46.1), ensure documentation confirms the presence of ring sideroblasts in bone marrow samples and refractory anemia that does not respond to standard treatments. Verify that the diagnosis aligns with MDS classification criteria and that any associated cytopenias or complications are appropriately documented.